Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase III Study of Radiotherapy With or Without Adjuvant C/T in Advanced Stage Nasopharyngeal Carcinoma Patients

This study has been terminated.
Sponsor:
Collaborators:
National Taiwan University Hospital
Tri-Service General Hospital
Kaohsiung Medical University
Kaohsiung Veterans General Hospital.
Taipei Veterans General Hospital, Taiwan
Mackay Memorial Hospital
Information provided by:
National Health Research Institutes, Taiwan
ClinicalTrials.gov Identifier:
NCT00201344
First received: September 13, 2005
Last updated: March 25, 2010
Last verified: June 2009

September 13, 2005
March 25, 2010
November 1994
Not Provided
overall survival, relapse free survival,distant metastasis and local-regional control rates.
Same as current
Complete list of historical versions of study NCT00201344 on ClinicalTrials.gov Archive Site
toxicities of the two treatment methods.
Same as current
Not Provided
Not Provided
 
A Phase III Study of Radiotherapy With or Without Adjuvant C/T in Advanced Stage Nasopharyngeal Carcinoma Patients
A Phase III Study of Radiotherapy With or Without Adjuvant Chemotherapy in Advanced Stage Nasopharyngeal Carcinoma Patients
  • To investigate the efficacy of adjuvant PFL chemotherapy after radiotherapy vs radiotherapy alone in AJC stage IV nasopharyngeal carcinoma patients. The endpoints of the study includes : overall survival, relapse free survival, distant metastasis and local-regional control rates.
  • To evaluate the toxicities of the two treatment methods.

The head and neck contracts study tested induction and maintenance chemotherapy in patients with advanced head and neck cancers.There were no significant differences in survival between the two groups, but disease free survival was prolonged in the maintenance arm and not in the induction arm. Time to and frequency of distant metastases as the first site of relapse were significantly better for those on the maintenance arm. Many trials, designed several years ago, delivered single agent chemotherapy and were not particularly intensive. Most clinical trials were dealing with a heterogenous group of head and neck cancer patients. We felt that a better choice of adjuvant chemotherapy on cancers should include: (1) localized cancers with high metastatic potential following effective local treatment; (2) effective chemotherapy available; (3) chemotherapy should be intensive and effective enough to avoid the development of drug resistance. Of course, NPC had long been regarded as one of the most suitable head and neck cancers that may benefit from adjuvant chemotherapy due to its unique high response rate to chemotherapy and high metastatic potential after radiotherapy for localized, advanced staged disease.

If radiotherapy plus adjuvant chemotherapy can improve the treatment results of standard radiotherapy by increasing the survival rate, decreasing the metastatic rate and local recurrence rate, then many NPC patients may benefit.

Therefore, we propose this phase III study of radiotherapy with or without adjuvant PFL chemotherapy in advanced stage NPC patients.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Nasopharyngeal Carcinoma
Drug: Cisplatin,5-FU,Leucovorin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
320
January 2000
Not Provided

Inclusion Criteria:

  • Patients must have histologically proven nasopharyngeal carcinoma who have just completed curative radiotherapy treatment.
  • Original stage must be stage IV disease (M0)
  • Patients must have a complete response, partial response or stable disease assessed 4 weeks after radiotherapy.
  • Performance status scale ECOG grade 0,1.
  • Creatinine ≦ 1.5mg/dl and bilirubin ≦ 2.0mg/dl, WBC ≧ 3,000/mm3 and PLT ≧ 100,000/mm3,or Creatinine Clearance > 45ml/min if Creatinine > 1.5mg/dl.
  • Patients must be younger than 70 year-old.
  • Patients must give signed informed consent.

Exclusion Criteria:

  • Patients had progressive disease after radiotherapy
  • Patients had evidence of distant metastasis.
  • Patients had completed radiotherapy for more than 7 weeks.
  • The presence of life-threatening illness
  • History of prior malignancy excluding basal cell carcinoma or squamous carcinoma of the skin or in-situ cervical cancer within 3 years of the diagnosis of NPC cancer.
  • Previous chemotherapy.
  • Pregnancy.
Both
up to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
NCT00201344
T1394
Not Provided
Not Provided
National Health Research Institutes, Taiwan
  • National Taiwan University Hospital
  • Tri-Service General Hospital
  • Kaohsiung Medical University
  • Kaohsiung Veterans General Hospital.
  • Taipei Veterans General Hospital, Taiwan
  • Mackay Memorial Hospital
Principal Investigator: Kwan-Hwa Chi, MD, Taiwan cooperative oncology group
National Health Research Institutes, Taiwan
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP